文献速递免疫规划卫生政策与健康促进

泰国儿童肺炎球菌结合疫苗成本效果分析更新

An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
PubMed 文献 · Vaccine · 2019-07-04

该研究采用Markov模型从社会视角评估泰国儿童接种PCV10和PCV13相比不接种的成本效果。基础分析显示PCV10的ICER为170,437泰铢/QALY,PCV13为73,674泰铢/QALY;考虑群体效应时两者均具成本效果。以160,000泰铢/QALY为阈值,PCV13有93%概率具成本效果。

要点

  • 基础分析中PCV13的ICER为73,674泰铢/QALY,低于阈值具成本效果。
  • PCV10的ICER为170,437泰铢/QALY,超过阈值不具成本效果。
  • 考虑群体效应时,PCV10和PCV13均成本更低且QALY更高。

核心结论

  • 在当前价格下,PCV13在泰国具成本效果,而PCV10不具成本效果。
  • 当考虑群体效应时,PCV10和PCV13均具成本效果。

研究设计与样本

  • 采用Markov模型,从社会视角,终身时间跨度,成本和结果按3%贴现。
  • 基础分析基于2+1剂次接种程序及五年保护期,未考虑群体效应。
  • 输入参数来自综合文献回顾,成本基于泰国国家电子数据库并转换为2017年价值。

主要发现

  • 基础分析中,PCV10的ICER为170,437泰铢/QALY,PCV13的ICER为73,674泰铢/QALY。
  • 考虑群体效应时,与不接种相比,PCV10和PCV13均成本更低且QALY更高。
  • 概率敏感性分析显示,在支付意愿阈值160,000泰铢/QALY下,PCV13具成本效果的概率为93%,PCV10为4.7%,不接种为2.3%。

关键数值与推荐

  • 成本效果阈值设定为160,000泰铢/QALY。
  • 基础分析ICER:PCV10为170,437泰铢/QALY,PCV13为73,674泰铢/QALY。
  • 概率敏感性分析中PCV13、PCV10和不接种具成本效果的概率分别为93%、4.7%和2.3%。

临床怎么用

  • 在泰国当前价格下,PCV13相比不接种具成本效果,可优先考虑。
  • 若群体效应显著,PCV10和PCV13均可作为成本效果方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A previous cost-effectiveness analysis (CEA) showed that Pneumococcal Conjugate Vaccine (PCV) 10 and PCV13 were not cost-effective for universal immunization among children in Thailand. Given recent changes in the evidence of efficacy, herd effects and price, a CEA of PCVs should be revisited. This study aimed to determine the cost-effectiveness of PCV10 and PCV13 compared to no PCV vaccination in Thai children. MATERIAL AND METHODS: A Markov model was developed under a societal perspective with a lifetime horizon. Inputs were derived from a comprehensive literature review. Costs were calculated using the Thai National Electronic Database and converted to the year 2017 value. All costs and outcomes were discounted at a rate of 3%. The findings were reported as incremental cost-effectiveness ratios (ICERs) in Thai Baht (THB) per quality-adjusted life year (QALY) gained. Sensitivity analyses were performed. A cost-effectiveness acceptability curve was generated with the cost-effectiveness threshold of 160,000 THB/QALY. RESULTS: Base-case analysis of 2 + 1 dose schedule and five-year protection, with no consideration of herd effect showed that ICER for PCV10 was 170,437 THB/QALY, while ICER for PCV13 was 73,674 THB/QALY. With consideration of herd effect, both PCV10 and PCV13 had lower costs and higher QALYs compared to no PCV vaccination. Based on our probabilistic sensitivity analysis at willingness-to-pay of 160,000 THB/QALY, PCV13 had 93% of being cost-effective, while 4.7% and 2.3%, for PCV10 and no PCV vaccination, respectively. CONCLUSION: At current prices, PCV13 is cost-effective, while PCV10 is not cost-effective in Thailand. When considering herd-effect, both PCV10 and PCV13 are cost-effective.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dilokthornsakul P, Kengkla K, Saokaew S, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019. PMID: 31280944. doi:10.1016/j.vaccine.2019.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。